{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["15(1)"],"submitter":["Khan Z"],"pubmed_abstract":["<h4>Background</h4>Dose-limiting toxicities significantly impact the benefit/risk profile of many drugs. Whole genome sequencing (WGS) in patients receiving drugs with dose-limiting toxicities can identify therapeutic hypotheses to prevent these toxicities. Chemotherapy-induced peripheral neuropathy (CIPN) is a common dose-limiting neurological toxicity of chemotherapies with no effective approach for prevention.<h4>Methods</h4>We conducted a genetic study of time-to-first peripheral neuropathy event using 30× germline WGS data from whole blood samples from 4900 European-ancestry cancer patients in 14 randomized controlled trials. A substantial number of patients in these trials received taxane and platinum-based chemotherapies as part of their treatment regimen, either standard of care or"],"journal":["Genome medicine"],"pagination":["45"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10286344"],"repository":["biostudies-literature"],"pubmed_title":["Whole genome sequencing across clinical trials identifies rare coding variants in GPR68 associated with chemotherapy-induced peripheral neuropathy."],"pmcid":["PMC10286344"],"pubmed_authors":["McCarthy MI","Bhangale T","Khan Z","Maiya V","Kaminker JS","Jung M","Crow M","Chandler GS","Mohindra R","Hackos DH"],"additional_accession":[]},"is_claimable":false,"name":"Whole genome sequencing across clinical trials identifies rare coding variants in GPR68 associated with chemotherapy-induced peripheral neuropathy.","description":"<h4>Background</h4>Dose-limiting toxicities significantly impact the benefit/risk profile of many drugs. Whole genome sequencing (WGS) in patients receiving drugs with dose-limiting toxicities can identify therapeutic hypotheses to prevent these toxicities. Chemotherapy-induced peripheral neuropathy (CIPN) is a common dose-limiting neurological toxicity of chemotherapies with no effective approach for prevention.<h4>Methods</h4>We conducted a genetic study of time-to-first peripheral neuropathy event using 30× germline WGS data from whole blood samples from 4900 European-ancestry cancer patients in 14 randomized controlled trials. A substantial number of patients in these trials received taxane and platinum-based chemotherapies as part of their treatment regimen, either standard of care or","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Jun","modification":"2026-05-29T17:39:59.675Z","creation":"2024-11-05T20:26:53.298Z"},"accession":"S-EPMC10286344","cross_references":{"pubmed":["37344884"],"doi":["10.1186/s13073-023-01193-4"]}}